

CLEARBRIDGE HEALTH LIMITED
(Company Registration No. 201001436C)

INCORPORATION OF SUBSIDIARY IN INDONESIA

The board of directors ("**Board**" or "**Directors**") of Clearbridge Health Limited (the "**Company**" and together with its subsidiaries, the "**Group**") wishes to announce that PT Clearbridge Health Indonesia, a wholly-owned subsidiary of the Company, had on 20 July 2018 incorporated a 49% owned subsidiary in Indonesia known as PT Clearbridge Medical Indonesia ("**CBMI**") (the "**Incorporation**"). The remaining 51% interest of CBMI is held by an existing employee of the Group.

As at the date of this announcement, the issued and paid-up share capital of CBMI is INR2,600,000,000 comprising 200,000 ordinary shares. The principal business activity of CBMI is the distribution of medical diagnostic and medical related products.

Although the Group owns less than half of the voting power of CBMI, the Board has determined that it is exposed, or has rights to variable return from its involvement with CBMI and has ability to affect those returns through its power over CBMI. Consequently, the Group consolidates this investment as a subsidiary of the Group.

The Incorporation was funded through internal resources and is not expected to have any material impact on the net tangible assets and earnings per share of the Group for the financial year ending 31 December 2018.

None of the Directors or controlling shareholders of the Company and their respective associates has any interest, direct or indirect, in the Incorporation, save for their shareholdings in the Company, if any.

BY ORDER OF THE BOARD

Yee Pinh Jeremy
Chief Executive Officer and Executive Director

24 July 2018

*This announcement has been prepared by the Company and its contents have been reviewed by the Company's sponsor, United Overseas Bank Limited (the "**Sponsor**"), for compliance with the relevant rules of the Singapore Exchange Securities Trading Limited (the "**SGX-ST**"). The Sponsor has not independently verified the contents of this announcement. This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement. The contact person for the Sponsor is Mr Chia Beng Kwan, Senior Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.*